α-Naphthoflavone inhibits 3T3-L1 pre-adipocytes differentiation via modulating p38MAPK signaling

International Journal of Clinical and Experimental Pathology

Volumn 6, Issue 2, 2013, Pages 168-178

  He, Qiqiang ^a   Huang, Caixuan ^b   Zhao, Lihua ^a   Feng, Jing ^a   Shi, Qun ^a   Wang, Dengshun ^c   Wang, Suqing ^a  

^a WUHAN UNIVERSITY   (China)

^b RENMIN HOSPITAL OF WUHAN UNIVERSITY   (China)

^c UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

Author keywords

Naphthoflavone; Adipogenesis; p38MAPK; PPAR

Indexed keywords

ALPHA NAPHTHOFLAVONE; ALPHA-NAPHTHOFLAVONE; BENZOFLAVONE DERIVATIVE; MITOGEN ACTIVATED PROTEIN KINASE P38; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA;

ADIPOCYTE; ADIPOGENESIS; ANIMAL; ARTICLE; CELL DIFFERENTIATION; CELL STRAIN 3T3; CELL SURVIVAL; CHEMISTRY; CYTOLOGY; DOSE RESPONSE; DRUG EFFECT; GENE EXPRESSION; GENETICS; LIPID METABOLISM; METABOLISM; MOUSE; OBESITY; P38MAPK; PPARΓ; SIGNAL TRANSDUCTION; STEM CELL; Α-NAPHTHOFLAVONE;

ADIPOGENESIS; P38MAPK; PPARΓ; Α-NAPHTHOFLAVONE;

3T3-L1 CELLS; ADIPOCYTES; ADIPOGENESIS; ANIMALS; BENZOFLAVONES; CELL DIFFERENTIATION; CELL SURVIVAL; DOSE-RESPONSE RELATIONSHIP, DRUG; GENE EXPRESSION; LIPID METABOLISM; MICE; OBESITY; P38 MITOGEN-ACTIVATED PROTEIN KINASES; PPAR GAMMA; SIGNAL TRANSDUCTION; STEM CELLS;

MLCS; MLOWN;

EID: 84879804486     PISSN: None     EISSN: 19362625     Source Type: Journal    
DOI: None     Document Type: Article

References (37)

1. Barton M. Childhood obesity: a life-long health risk. Acta Pharmacol Sin 2012; 33: 189-193.
2. Flie JS. Obesity wars: Molecular progress confronts an expanding epidemic. Cell 2004; 116: 337-350.
3. Barak Y, Nelson MC, Ong ES, Jones YZ, Ruiz-Lozano P, Chien KR, Koder A and Evans RM. PPAR gamma is required for placental, cardiac, and adipose tissue development. Mol Cell 1999; 4: 585-595.
4. Tanaka T, Yoshida N, Kishimoto T and Akira S. Defective adipocyte differentiation in mice lacking the C/EBP beta and/or C/EBP delta gene. Embo J 1997; 16: 7432-7443.
5. Farmer SR. Transcriptional control of adipocyte formation. Cell Metab 2006; 4: 263-73.
6. Vasudeva N, Yadav N and Sharma SK. Natural Products: A safest Approach for Obesity. Chin J of Integr Med 2012; 18: 473-480.
7. Harborne JB and Williams CA. Advances in flavonoid research since 1992. Phytochemistry 2000; 55: 481-504.
8. Ren WY, Qiao ZH, Wang HW, Zhu L and Zhang L. Flavonoids: Promising anticancer agents. Med Res Rev 2003; 23: 519-534.
9. Hollman PCH and Katan MB. Dietary flavonoids: Intake, health effects and bioavailability. Food Chem Toxicol 1999; 37: 937-942.
10. Riceevans CA, Miller NJ, Bolwell GP, Bramley PM and Pridham JB. Relative Antioxidant Activities of Plant-Derived Polyphenolic Flavonoids. Free Radical Res 1995; 22: 375-383.
11. Park HH, Lee S, Oh JM, Lee MS, Yoon KH, Park BH, Kim JW, Song H and Kim SH. Anti-inflammatory activity of fisetin in human mast cells (HMC-1). Pharmacol Res 2007; 55: 31-37.
12. Mojzis J, Hviscova K, Germanova D, Bukovicova D and Mirossay L. Protective effect of quercetin on ischemia/reperfusion-induced gastric mucosal injury in rats. Physiol Res 2001; 50: 501-506.
13. Rimbach G, Boesch-Saadatmandi C, Frank J, Fuchs D, Wenzel U, Daniel H, Hall WL and Weinberg PD. Dietary isoflavones in the prevention of cardiovascular disease - A molecular perspective. Food Chem Toxicol 2008; 46: 1308-1319.
14. Androutsopoulos VP, Papakyriakou A, Vourloumis D, Tsatsakis AM and Spandidos DA. Dietary flavonoids in cancer therapy and prevention: Substrates and inhibitors of cytochrome P450 CYP1 enzymes. Pharmacol & Therapeut 2010; 126: 9-20.
15. Craggs L and Kalaria RN. Revisiting dietary antioxidants, neurodegeneration and dementia. Neuroreport 2011; 22: 1-3.
16. Heiss C, Keen CL and Kelm M. Flavanols and cardiovascular disease prevention. Eur Heart J 2010; 31: 2583-U32.
17. Chen SF, Li ZL, Li WX, Shan ZM and Zhu W. Resveratrol inhibits cell differentiation in 3T3- L1 adipocytes via activation of AMPK. Can J Physiol and Pharm 2011; 9: 793-799.
18. Meydani M and Hasan ST. Dietary Polyphenols and Obesity. Nutrients 2010; 2: 737-751.
19. Overman A, Chuang CC and Mcintosh M. Quercetin attenuates inflammation in human macrophages and adipocytes exposed to macrophage- conditioned media. Int J Obesity 2011; 5: 1165-1172.
20. Cheon H, Woo YS, Lee JY, Kim HS, Kim HJ, Cho S, Won NH and Sohn J. Signaling pathway for 2, 3, 7, 8-tetrachlorodibenzo-p-dioxin-induced TNF-alpha production in differentiated THP-1 human macrophages. Exp Mol Med 2007; 39: 524-34.
21. Cheng YW, Li CH, Lee CC and Kang JJ. Alphanaphthoflavone induces vasorelaxation through the induction of extracellular calcium influx and NO formation in endothelium. N-S Arch Pharmacol 2003; 368: 377-385.
22. Hsiao G, Chang CY, Shen MY, Chou DS, Tzeng SH, Chen TF and Sheu JR. alpha-Naphthoflavone, a potent antiplatelet flavonoid, is mediated through inhibition of phospolipase C activity and stimulation of cyclic GMP formation (vol 53, pg 5179, 2005). J Agr Food Chem 2005; 53: 6954-6954.
23. Norris AW, Chen L, Fisher SJ, Szanto I, Ristow M, Jozsi AC, Hirshman MF, Rosen ED, Goodyear LJ, Gonzalez FJ, Spiegelman BM and Kahn CR. Muscle-specific PPARgamma deficient mice develop increased adiposity and insulin resistance but respond to thiazolidinediones. J Clin Invest 2003; 112: 608-18.
24. Bost F, Aouadi M, Caron L and Binétruy B. The role of MAPKs in adipocyte differentiation and obesity. Biochimie 2005; 87: 51-6.
25. Matsumoto T, Turesson I, Book M, Gerwins P and Claesson-Welsh L. p38 MAP kinase negatively regulates endothelial cell survival, proliferation, and differentiation in FGF-2-stimulated angiogenesis. J Cell Biol 2002; 156: 149-160.
26. Uddin S, Ah-Kang J, Ulaszek J, Mahmud D and Wickrema A. Differentiation stage-specific activation of p38 mitogen-activated protein kinase isoforms in primary human erythroid cells. P Natl Acad Sci USA 2004; 101: 147-152.
27. Yuge L, Hide I, Kumagai T, Kumei Y, Takeda S, Kanno M, Sugiyama M, and Kataoka K. Cell differentiation and p38(MAPK) cascade are inhibited in human osteoblasts cultured in a three-dimensional clinostat. In Vitro Cellular Dev-An 2003; 39: 89-97.
28. Wang M, Wang JJ, Li JM, Park K, Qian XX, Ma JX and Zhang SX. Pigment epithelium-derived factor suppresses adipogenesis via inhibition of the MAPK/ERK pathway in 3T3-L1 preadipocytes. Am J Physiol-Endoc M 2009; 297: E1378-E1387.
29. Couillard C, Mauriège P, Imbeault P, Prud'homme D, Nadeau A, Tremblay A, Bouchard C and Després JP. Hyperleptinemia is more closely associated with adipose cell hypertrophy than with adipose tissue hyperplasia. Int J Obesity 2000; 24: 782-788.
30. Hsiao G, Chang CY, Shen MY, Chou DS, Tzeng SH, Chen TF and Sheu JR. alpha-naphthoflavone, a potent antiplatelet flavonoid, is mediated through inhibition of phospholipase C activity and stimulation of cyclic GMP formation. J Agr Food Chem 2005; 53: 5179-5186.
31. Rondanelli M, Klersy C, Iadarola P, Monteferrario F and Opizzi A. Satiety and amino-acid profile in overweight women after a new treatment using a natural plant extract sublingual spray formulation. Int J Obesity 2009; 33: 1174-1182.
32. Kaminski DA and Randall TD. Adaptive immunity and adipose tissue biology. Trends Immunol 2010; 31: 384-90.
33. Leff T and Granneman JG. Adipose Tissue in Health and Disease Preface. Adipose Tissue in Health and Disease 2010; Xix-Xx.
34. Bost F, Aouadi M, Caron L and Binetruy B. The role of MAPKs in adipocyte differentiation and obesity. Biochimie 2005; 87: 51-56.
35. Takenouchi T, Takayama Y and Takezawa T Cotreatment with dexamethasone and octanoate induces adipogenesis in 3T3-L1 cells. Cell Biol Int 2004; 28: 209-16.
36. Engelman JA, Lisanti MP and Scherer PE. Specific inhibitors of p38 mitogen-activated protein kinase block 3T3-L1 adipogenesis. J Biol Chem 1998; 273: 32111-32120.
37. Aouadi M, Laurent K, Prot M, Marchand-Brustel YL, Binetruy B and Bost F. Inhibition of p38MAPK increases adipogenesis from embryonic to adult stages. Diabetes 2006; 55: 281-289.